Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 865 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed, Refractory Multiple Myeloma Clear all

Conditions: Multiple Myeloma
Interventions: Mapatumumab, Bortezomib; Biological · Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Scottsdale, Arizona • La Jolla, California • Lecanto, Florida + 5 more

Conditions: Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Interventions: AlloStim-8; Biological
Lead sponsor: Mirror Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Multiple Myeloma
Interventions: PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide, PF-06863135 + pomalidomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Encinitas, California • La Jolla, California • San Diego, California + 21 more

Conditions: Plasma Cell Myeloma
Interventions: SAR442085; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Dexamethasone, Leflunomide, Pomalidomide; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Duarte, California • Huntington Beach, California • Lancaster, California + 5 more

Conditions: Neoplasm Malignant
Interventions: SAR442257; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Duarte, California • Miami, Florida • Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: TNB-383B; Drug
Lead sponsor: TeneoOne Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Multiple Myeloma
Interventions: BT062; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more

Conditions: Multiple Myeloma, Immune System Diseases
Interventions: CAR138 T Cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2039
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse, Other B Cell Lymphoma in Relapse, Plasma Cell Leukemia
Interventions: SNS01-T; Biological
Lead sponsor: Senesco Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Little Rock, Arkansas • Rochester, Minnesota • Hackensack, New Jersey + 2 more

Conditions: Multiple Myeloma
Interventions: VLX1570 and dexamethasone; Drug
Lead sponsor: Vivolux AB; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
Interventions: DKN-01; Drug
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 8
States / cities: Scottsdale, Arizona • Albany, New York • Greenville, South Carolina + 5 more

Conditions: Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
Interventions: Panobinostat, Dexamethasone, MLN9708; Drug
Lead sponsor: Jason Valent; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Aurora, Colorado • Durham, North Carolina • Canton, Ohio

Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone; Drug · Device
Lead sponsor: Natalie Callander; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: SIM0500; Drug
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 5 more

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: University of Rochester; Other
Eligibility: Up to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions: Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Dexamethasone, Daratumumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 33
States / cities: Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more

Conditions: Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions: AMG 397, Dexamethasone, Azacitidine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more

Conditions: Multiple Myeloma
Interventions: CX-4945; Drug
Lead sponsor: Cylene Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Kettering, Ohio • Portland, Oregon • Springfield, Oregon + 3 more

Conditions: Multiple Myeloma
Interventions: Bortezomib; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Search by objective public record fields.

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

A Study of VLX1570 and Dexamethasone in Myeloma Patients

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Study of CAR-T Therapy in Older Patients

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)